Guilty Plea By Former Astra USA Employee
Stefan Solvell, a former executive of Astra USA, a subsidiary of theSwedish pharmaceutical company Astra, has entered a plea of guilty to a charge of filing a US federal income-tax return for 1995 that allegedly understated the amount he owed by $10,000.
It is understood that Mr Solvell, if found guilty, could face a sentence of three years in prison and fines of up to $250,000. He may reach a plea agreement which could give him a minimum sentence. Mr Solvell was the deputy to Lars Bildman at Astra's US unit. Mr Bildman is facing charges of stealing from the firm, and other charges of misconduct (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze